Suppr超能文献

门静脉血栓形成:患病率、患者特征及终生风险:一项基于23796例连续尸检的人群研究

Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies.

作者信息

Ogren Mats, Bergqvist David, Björck Martin, Acosta Stefan, Eriksson Henry, Sternby Nils H

机构信息

Department of Vascular Surgery, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.

出版信息

World J Gastroenterol. 2006 Apr 7;12(13):2115-9. doi: 10.3748/wjg.v12.i13.2115.

Abstract

AIM

To assess the lifetime cumulative incidence of portal venous thrombosis (PVT) in the general population.

METHODS

Between 1970 and 1982, 23,796 autopsies, representing 84% of all in-hospital deaths in the Malmö city population, were performed, using a standardised protocol including examination of the portal vein. PVT patients were characterised and the PVT prevalence at autopsy, an expression of life-time cumulative incidence, assessed in high-risk disease categories and expressed in terms of odds ratios and 95% CI.

RESULTS

The population prevalence of PVT was 1.0%. Of the 254 patients with PVT 28% had cirrhosis, 23% primary and 44% secondary hepatobiliary malignancy, 10% major abdominal infectious or inflammatory disease and 3% had a myeloproliferative disorder. Patients with both cirrhosis and hepatic carcinoma had the highest PVT risk, OR 17.1 (95% CI 11.1-26.4). In 14% no cause was found; only a minority of them had developed portal-hypertension-related complications.

CONCLUSION

In this population-based study, PVT was found to be more common than indicated by previous clinical series. The markedly excess risk in cirrhosis and hepatic carcinoma should warrant an increased awareness in these patients for whom prospective studies of directed intervention might be considered.

摘要

目的

评估普通人群门静脉血栓形成(PVT)的终生累积发病率。

方法

1970年至1982年间,对23796例尸体进行了解剖,这些尸体占马尔默市所有住院死亡人数的84%,采用标准化方案,包括对门静脉进行检查。对PVT患者进行特征分析,并评估尸检时PVT的患病率,即终生累积发病率的一种表达方式,在高危疾病类别中进行评估,并以比值比和95%置信区间表示。

结果

PVT的人群患病率为1.0%。在254例PVT患者中,28%患有肝硬化,23%患有原发性和44%患有继发性肝胆恶性肿瘤,10%患有重大腹部感染或炎症性疾病,3%患有骨髓增殖性疾病。同时患有肝硬化和肝癌的患者PVT风险最高,比值比为17.1(95%置信区间为11.1 - 26.4)。14%的患者未发现病因;其中只有少数人出现了门静脉高压相关并发症。

结论

在这项基于人群的研究中,发现PVT比以往临床系列报道的更为常见。肝硬化和肝癌患者中明显过高的风险应促使对这些患者提高认识,对于他们可能需要考虑进行前瞻性的定向干预研究。

相似文献

2
Risk factors associated with portal vein thrombosis in liver cirrhosis: A case-control study.
Ter Arkh. 2019 Mar 18;91(2):73-81. doi: 10.26442/00403660.2019.02.000153.
4
Portal vein thrombosis: what is new?
Ann Hepatol. 2015 Jan-Feb;14(1):20-7.
5
Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort.
J Gastroenterol Hepatol. 2019 Jun;34(6):1088-1092. doi: 10.1111/jgh.14501. Epub 2018 Nov 4.
9
Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome.
BMC Gastroenterol. 2017 Oct 25;17(1):112. doi: 10.1186/s12876-017-0668-8.

引用本文的文献

3
The etiology of chronic splanchnic vein thrombosis in adults: a two-center analysis.
Am J Blood Res. 2025 Feb 15;15(1):1-8. doi: 10.62347/NMIJ8301. eCollection 2025.
4
Endovascular management of acute portal vein thrombosis in pediatric liver transplant recipients less than 20 kg.
Pediatr Radiol. 2025 May;55(5):957-964. doi: 10.1007/s00247-025-06189-3. Epub 2025 Feb 14.
5
Acute splanchnic venous thrombosis following laparoscopic sleeve gastrectomy: A case report.
Int J Surg Case Rep. 2025 Mar;128:111028. doi: 10.1016/j.ijscr.2025.111028. Epub 2025 Feb 8.
7
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion.
Hepatol Int. 2025 Feb;19(1):106-117. doi: 10.1007/s12072-024-10762-7. Epub 2025 Jan 9.
8
Portal Vein Thrombosis in COVID-19: An Underdiagnosed Disease?
J Clin Med. 2024 Sep 21;13(18):5599. doi: 10.3390/jcm13185599.
9
Large-Bore Mechanical Thrombectomy for Subacute Portal Vein Thrombosis in Patient With Acute Bleeding.
Gastro Hep Adv. 2022 Apr 5;1(4):627-630. doi: 10.1016/j.gastha.2022.03.006. eCollection 2022.
10
Asymptomatic Extrahepatic Portal Venous Obstruction: A Case Report.
Cureus. 2024 Jul 7;16(7):e64037. doi: 10.7759/cureus.64037. eCollection 2024 Jul.

本文引用的文献

1
Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis.
World J Gastroenterol. 2005 Feb 28;11(8):1215-9. doi: 10.3748/wjg.v11.i8.1215.
3
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Chest. 2004 Sep;126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S.
4
Extrahepatic portal vein thrombosis in children: etiology and long-term follow-up.
J Clin Gastroenterol. 2004 Apr;38(4):368-72. doi: 10.1097/00004836-200404000-00013.
5
Incidence of acute thrombo-embolic occlusion of the superior mesenteric artery--a population-based study.
Eur J Vasc Endovasc Surg. 2004 Feb;27(2):145-50. doi: 10.1016/j.ejvs.2003.11.003.
6
Extrahepatic portal vein thrombosis: aetiology and determinants of survival.
Gut. 2001 Nov;49(5):720-4. doi: 10.1136/gut.49.5.720.
7
Portal vein thrombosis associated with antiphospholipid syndrome.
J Gastroenterol. 2001 Aug;36(8):574-8. doi: 10.1007/s005350170063.
8
Changing perspectives in portal vein thrombosis.
Scand J Gastroenterol Suppl. 2000(232):69-73.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验